TEVA PHARMACEUTICAL INDUSTRIES LTD
For the period ended Mar 31, 2026. Filed Apr 29, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed Apr 29, 2026
TEVA$42.61+2.0%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated statements of changes in equity
| Teva shareholders’ equity | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Ordinary shares | |||||||||
| Number ofshares (inmillions) | Stated value | Additionalpaid-in capital | Retainedearnings(accumulateddeficit) | Accumulated othercomprehensiveincome (loss) | Treasuryshares | Total Tevashareholders’equity | Non-controllinginterests | Total equity | |
| (U.S. dollars in millions) | |||||||||
| Balance at December 31, 2025 | 1,256 | 58 | 28,133 | (13,762) | (2,391) | (4,128) | 7,910 | 4 | 7,914 |
| Net Income (loss) | 369 | 369 | * | 369 | |||||
| Other comprehensive income (loss) | (121) | (121) | * | (121) | |||||
| Issuance of Shares | 15 | * | * | ||||||
| Proceeds from exercise of options | 26 | 26 | 26 | ||||||
| Stock-based compensation expense | 43 | 43 | 43 | ||||||
| Balance at March 31, 2026 | 1,271 | $59 | $28,203 | $(13,394) | $(2,512) | $(4,128) | $8,228 | $4 | $8,232 |
| * | Represents an amount less than $0.5 million. |
|---|
| Teva shareholders’ equity | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Ordinary shares | |||||||||
| Number ofshares (inmillions) | Stated value | Additionalpaid-in capital | Retainedearnings(accumulateddeficit) | Accumulated othercomprehensiveincome (loss) | Treasuryshares | Total Tevashareholders’equity | Non-controllinginterests | Total equity | |
| (U.S. dollars in millions) | |||||||||
| Balance at December 31, 2024 | 1,240 | 58 | 27,764 | (15,173) | (3,148) | (4,128) | 5,373 | 7 | 5,380 |
| Net Income (loss) | 214 | 214 | * | 214 | |||||
| Other comprehensive income (loss) | 473 | 473 | * | 473 | |||||
| Issuance of shares | 13 | * | * | * | |||||
| Proceeds from exercise of options | 3 | 3 | 3 | ||||||
| Stock-based compensation expense | 34 | 34 | 34 | ||||||
| Purchase of shares from non-controlling interests** | 165 | 165 | 165 | ||||||
| Balance at March 31, 2025 | 1,253 | $58 | $27,965 | $(14,958) | $(2,675) | $(4,128) | $6,262 | $7 | $6,269 |
| * | Represents an amount less than $0.5 million. |
|---|
| ** | In connection with the sale of Teva’s business venture in Japan. |
|---|
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.